Butidrin

Butidrin
Nazivi
	IUPAC naziv 2-(Butan-2-ilamino)-1-(5,6,7,8-tetrahidronaftalen-2-il)etanol
	Drugi nazivi Butedrin; Butidrin; Hidrobutamin; Idrobutamin
Identifikacija
CAS broj	7433-10-5 ;
3D model (Jmol)	interaktivna slika;
ChEBI	CHEBI:135008;
ChemSpider	14445;
PubChem C ID	15177;
UNII	N2S0PKP5L5 ;
	SMILES CCC(C)NCC(C1=CC2=C(CCCC2)C=C1)O; ; ; ; ; ;
Svojstva
Hemijska formula	C16H25NO
Molarna masa	247,38 g·mol−1
	Ukoliko nije drugačije napomenuto, podaci se odnose na standardno stanje materijala (na 25 °C [77 °F], 100 kPa).
	Reference infokutije

Butidrin (INN) (robne marke Betablok, Butidrat, Recetan), ili butedrin ili butidrin, takođe poznat kao hidrobutamin ili idrobutamin, je beta blokator srodan sa pronetalolom^[3] i propranololom^[4] koji je razvijen tokom 1960-ih.^[5]^[6] Slično nekim drugim beta blokatorima, butidrin takođe poseduje lokalna anestetička svojstva.^[7]

Reference[уреди | уреди извор]

^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди
^ Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.
^ Bristol JA (1986). Cardiovascular drugs. John Wiley & Sons, Incorporated. стр. 111. ISBN 978-0-471-09228-5.
^ Drug Metabolism Reviews. Marcel Dekker. 1972.
^ Morton IK, Hall JM (6. 12. 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. стр. 58—. ISBN 978-94-011-4439-1.
^ Elks J (14. 11. 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. стр. 197—. ISBN 978-1-4757-2085-3.
^ Charlier R (1971). Antianginal drugs: pathophysiological, haemodynamic, methodological, pharmacological, biochemical and clinical basis for their use in human therapeutics. Springer-Verlag. ISBN 978-3-540-05365-1.

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today. 15 (23-24): 1052—7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003. уреди

[2] Evan E. Bolton; Yanli Wang; Paul A. Thiessen; Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry. 4: 217—241. doi:10.1016/S1574-1400(08)00012-1.

[Bristol1986-3] Bristol JA (1986). Cardiovascular drugs. John Wiley & Sons, Incorporated. стр. 111. ISBN 978-0-471-09228-5.

[4] Drug Metabolism Reviews. Marcel Dekker. 1972.

[MortonHall2012-5] Morton IK, Hall JM (6. 12. 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. стр. 58—. ISBN 978-94-011-4439-1.

[Elks2014-6] Elks J (14. 11. 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. стр. 197—. ISBN 978-1-4757-2085-3.

[Charlier1971-7] Charlier R (1971). Antianginal drugs: pathophysiological, haemodynamic, methodological, pharmacological, biochemical and clinical basis for their use in human therapeutics. Springer-Verlag. ISBN 978-3-540-05365-1.

[1]

[2]

[3]

[4]

[5]

[6]

[7]